The current role of precision surgery in oligometastatic prostate cancer

ESMO Open - Tập 7 - Trang 100597 - 2022
M. von Deimling1,2, P. Rajwa1,3, D. Tilki2,4, A. Heidenreich1,5, M. Pallauf1,6, A. Bianchi1,7, T. Yanagisawa1,8, T. Kawada1,9, P.I. Karakiewicz10, P. Gontero11, B. Pradere1,12, G. Ploussard12, M. Rink2, S.F. Shariat1,13,14,15,16,17,18
1Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
2Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
3Department of Urology, Medical University of Silesia, Zabrze, Poland
4Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
5Department of Urology, University Hospital Cologne, Cologne, Germany
6Department of Urology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria
7Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
8Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
9Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
10Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada
11Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy
12Department of Urology, La Croix Du Sud Hospital, Quint-Fonsegrives, France
13Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan
14Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
15Department of Urology, Weill Cornell Medical College, New York, USA
16Department of Urology, University of Texas Southwestern, Dallas, USA
17Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
18Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia

Tài liệu tham khảo

Desai, 2022, Trends in incidence of metastatic prostate cancer in the US, JAMA Netw Open, 5, 1, 10.1001/jamanetworkopen.2022.2246

Zhu, 2021, Epidemiology and genomics of prostate cancer in Asian men, Nat Rev Urol, 18, 282, 10.1038/s41585-021-00442-8

Bray, 2018, Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, Ca Cancer J Clin, 68, 394, 10.3322/caac.21492

Hellman, 1995, Oligometastases. J Clin Oncol, 13, 8, 10.1200/JCO.1995.13.1.8

Katipally, 2022, The oligometastatic spectrum in the era of improved detection and modern systemic therapy, Nat Rev Clin Oncol, 10.1038/s41571-022-00655-9

Francini, 2018, Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC), Prostate, 78, 889, 10.1002/pros.23645

Guckenberger, 2020, Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation, Lancet Oncol, 21, e18, 10.1016/S1470-2045(19)30718-1

Gillessen, 2020, Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019, Eur Urol, 77, 508, 10.1016/j.eururo.2020.01.012

Gandaglia, 2015, Impact of the site of metastases on survival in patients with metastatic prostate cancer, Eur Urol, 68, 325, 10.1016/j.eururo.2014.07.020

Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial, J Clin Oncol, 36, 1080, 10.1200/JCO.2017.75.3657

Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7

Flanigan, 2001, Nephrectomy followed by interferon alpfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N Engl J Med, 345, 1655, 10.1056/NEJMoa003013

Bristow, 2002, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era, J Clin Oncol, 20, 1248, 10.1200/JCO.2002.20.5.1248

Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. 2022. Edn. presented at the EAU Annual Congress Amsterdam 2022. EAU Guidelines Office, Arnhem, The Netherlands. Available at http://uroweb.org/guidelines/compilations-of-all-guidelines/. Accessed September 30, 2022.

Grubmüller, 2018, PSMA ligand PET/MRI for primary prostate cancer : staging performance and clinical impact, Clin Cancer, 24, 6300, 10.1158/1078-0432.CCR-18-0768

Morris, 2021, Diagnostic performance of 18 F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer : results from the CONDOR phase III, multicenter study, Clin Cancer Res, 27, 3674, 10.1158/1078-0432.CCR-20-4573

Fendler, 2019, Assessment of 68 Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer a prospective single-arm clinical trial, JAMA Oncol, 5, 856, 10.1001/jamaoncol.2019.0096

Hope, 2021, Diagnostic accuracy of 68 Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection a multicenter prospective phase 3 imaging trial, JAMA Oncol, 7, 1635, 10.1001/jamaoncol.2021.3771

Hövels, 2008, The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer : a meta-analysis, Clin Radiol, 63, 387, 10.1016/j.crad.2007.05.022

Beresford, 2010, A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence, Clin Oncol, 22, 46, 10.1016/j.clon.2009.10.015

De Visschere, 2019, A systematic review on the role of imaging in early recurrent prostate cancer, Eur Urol Oncol, 2, 47, 10.1016/j.euo.2018.09.010

Gomez, 2004, Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?, BJU Int, 94, 299, 10.1111/j.1464-410X.2004.04927.x

Perera, 2019, Eur Urol, 77, 403, 10.1016/j.eururo.2019.01.049

Kimura, 2020, Performance of [68 Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection : a systematic review and meta-analysis, Prostate Cancer Prostatic Dis, 23, 1, 10.1038/s41391-019-0156-z

Zaorsky, 2021, Salvage therapy for prostate cancer after radical prostatectomy, Nat Rev Urol, 18, 643, 10.1038/s41585-021-00497-7

Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147

Emmett, 2020, 3-Year freedom from progression after 68Ga-PSMA PET/CT–triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial, J Nucl Med, 61, 866, 10.2967/jnumed.119.235028

Grubmüller, 2018, Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making, Eur J Nucl Med Mol Imaging, 45, 235, 10.1007/s00259-017-3858-2

Farolfi, 2021, Positron emission tomography and whole-body magnetic resonance imaging for metastasis-directed therapy in hormone-sensitive oligometastatic prostate cancer after primary radical treatment: a systematic review, Eur Urol Oncol, 4, 714, 10.1016/j.euo.2021.02.003

Fossati, 2020, Newly diagnosed oligometastatic prostate cancer : current controversies and future developments, Eur Urol Oncol

Herlemann, 2017, Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients, Oncotarget, 8, 84180, 10.18632/oncotarget.21118

Deijen, 2021, PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer, Clin Transl Radiat Oncol, 30, 1, 10.1016/j.ctro.2021.06.004

Palma, 2020, Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial, J Clin Oncol, 38, 2830, 10.1200/JCO.20.00818

Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853

Maurer, 2016, Current use of PSMA-PET in prostate cancer management, Nat Rev Urol, 13, 226, 10.1038/nrurol.2016.26

Evangelista, 2022, [68 Ga] Ga-PSMA versus [18 F] PSMA positron emission tomography/computed tomography in the staging of primary and recurrent prostate cancer. A systematic review of the literature, Eur Urol Oncol, 5, 273, 10.1016/j.euo.2022.03.004

Abufaraj, 2019, Prospective evaluation of the performance of [68Ga] Ga-PSMA-11 PET/CT (MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy, Eur J Nucl Med Mol Imaging, 46, 2169, 10.1007/s00259-019-04361-0

Mandel, 2020, Accuracy of 68Ga-prostate-specific membrane antigen positron emission tomography for the detection of lymph node metastases before salvage lymphadenectomy, Eur Urol Focus, 6, 71, 10.1016/j.euf.2018.07.025

Ploussard, 2018, Salvage lymph node dissection for nodal recurrent prostate cancer : a systematic review, Eur Urol, 76, 493, 10.1016/j.eururo.2018.10.041

Huebner, 2022, Feasibility and optimal time point of [68 Ga] gallium-labeled prostate-specific membrane antigen ligand positron emission tomography imaging in patients undergoing cytoreductive surgery after systemic therapy for primary oligometastatic prostate cancer, Eur Urol Open Sci, 40, 117, 10.1016/j.euros.2022.04.003

Psaila, 2009, The metastatic niche: adapting the foreign soil, Nat Rev Cancer, 9, 285, 10.1038/nrc2621

Kang, 2022, Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer, Cancer Lett, 530, 156, 10.1016/j.canlet.2022.01.015

Furesi, 2021, Emerging players in prostate cancer–bone niche communication, Trends Cancer, 7, 112, 10.1016/j.trecan.2020.09.006

Kim, 2009, Tumor self-seeding by circulating cancer cells, Cell, 139, 1315, 10.1016/j.cell.2009.11.025

Tzelepi, 2011, Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment, J Clin Oncol, 29, 2574, 10.1200/JCO.2010.33.2999

Connor, 2020, Cytoreductive treatment strategies for de novo metastatic prostate cancer, Nat Rev Clin Oncol, 17, 168, 10.1038/s41571-019-0284-3

Kadmon, 1982, Treatment of a metastatic prostate derived tumor with surgery and chemotherapy, J Urol, 127, 1238

Linxweiler, 2022, Primary tumor resection decelerates disease progression in an orthotopic mouse model of metastatic prostate cancer, Cancers (Basel), 14, 1, 10.3390/cancers14030737

Niklas, 2021, Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?, World J Urol, 39, 3231, 10.1007/s00345-020-03568-3

Qin, 2012, Tumor cytoreduction results in better response to androgen ablation-a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer, Urol Oncol Semin Orig Investig, 30, 145

Boevé, 2018, Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial, Eur Urol, 75, 410, 10.1016/j.eururo.2018.09.008

Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3

Burdett, 2019, Prostate radiotherapy for metastatic hormone-sensitive prostate cancer : a STOPCAP systematic review and meta-analysis, Eur Urol, 76, 115, 10.1016/j.eururo.2019.02.003

Fizazi, 2022, Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design, Lancet, 399, 1695, 10.1016/S0140-6736(22)00367-1

Heidenreich, 2015, Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study, J Urol, 193, 832

Fossati, 2015, Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study, Eur Urol, 67, 3, 10.1016/j.eururo.2014.08.056

Gratzke, 2014, Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry, Eur Urol, 66, 602, 10.1016/j.eururo.2014.04.009

Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor ? A SEER-based study, Eur Urol, 65, 1058, 10.1016/j.eururo.2013.11.012

Jang, 2018, Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases, BJU Int, 121, 225, 10.1111/bju.13992

Leyh-Bannurah, 2017, Local therapy improves survival in metastatic prostate cancer, Eur Urol, 72, 118, 10.1016/j.eururo.2017.03.020

Löppenberg, 2017, The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis : a national cancer data base analysis, Eur Urol, 72, 14, 10.1016/j.eururo.2016.04.031

Wang, 2018, The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis, Biosci Rep, 38, 1, 10.1042/BSR20171379

Satkunasivam, 2015, Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer : a SEER-medicare analysis, J Urol, 194, 378

Steuber, 2017, Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study, Eur Urol Focus, 3, 646, 10.1016/j.euf.2017.06.016

Knipper, 2020, Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H, World J Urol, 38, 1459, 10.1007/s00345-019-02950-0

Sooriakumaran, 2016, A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation, Eur Urol, 69, 788, 10.1016/j.eururo.2015.05.023

Heidenreich, 2018, Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases, Eur Urol Oncol, 1, 46, 10.1016/j.euo.2018.03.002

Gandaglia, 2017, Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up, Eur Urol, 72, 289, 10.1016/j.eururo.2016.08.040

Buelens, 2022, Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study), BJU Int, 129, 699, 10.1111/bju.15553

Lumen, 2021, The role of cytoreductive radical prostatectomy in the treatment of newly diagnosed low-volume metastatic prostate cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) registry, Eur Urol Open Sci, 29, 68, 10.1016/j.euros.2021.05.006

Sooriakumaran, 2022, Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial, BJU Int, 130, 43, 10.1111/bju.15669

Preisser, 2018, Comparison of perioperative outcomes between cytoreductive radical prostatectomy and radical prostatectomy for nonmetastatic prostate cancer, Eur Urol, 74, 693, 10.1016/j.eururo.2018.07.006

Won, 2013, Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer, BJU Int, 112, 250, 10.1111/bju.12169

Chaloupka, 2021, Health-related quality of life following cytoreductive radical prostatectomy in patients with de-novo oligometastatic prostate cancer, Cancers (Basel), 13, 1, 10.3390/cancers13225636

Ranasinghe, 2020, The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer, BJU Int, 125, 792, 10.1111/bju.15055

Kim, 2022, Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy, Prostate Int, 10, 75, 10.1016/j.prnil.2022.03.001

Gundem, 2015, The evolutionary history of lethal metastatic prostate cancer, Nature, 520, 353, 10.1038/nature14347

Connor, 2020, Targeting oligometastasis with stereotactic ablative radiation therapy or surgery in metastatic hormone-sensitive prostate cancer: a systematic review of prospective clinical trials, Eur Urol Oncol, 3, 582, 10.1016/j.euo.2020.07.004

Ost, 2015, Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature, Eur Urol, 67, 852, 10.1016/j.eururo.2014.09.004

Steuber, 2019, Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study, Eur Urol Focus, 5, 1007, 10.1016/j.euf.2018.02.015

Bravi, 2020, Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought, Eur Urol, 78, 661, 10.1016/j.eururo.2020.06.043

Maurer, 2018, 99mTechnetium-based prostate-specific membrane antigen – radioguided surgery in recurrent prostate cancer, Eur Urol, 75, 659, 10.1016/j.eururo.2018.03.013

Knipper, 2019, Metastases-yield and prostate-specific antigen kinetics following salvage lymph node dissection for prostate cancer: a comparison between conventional surgical approach and prostate-specific membrane antigen-radioguided surgery, Eur Urol Focus, 5, 50, 10.1016/j.euf.2018.09.014

Knipper, 2022, Cohort study of oligorecurrent prostate cancer patients : oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen – radioguided surgery, Eur Urol, 10.1016/S0302-2838(22)00594-2

Rigatti, 2011, Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C] choline positron emission tomography/computed tomography, Eur Urol, 60, 935, 10.1016/j.eururo.2011.07.060

Suardi, 2015, Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years, Eur Urol, 67, 299, 10.1016/j.eururo.2014.02.011

Fossati, 2019, Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis, Eur Urol, 75, 176, 10.1016/j.eururo.2018.09.009

De Bruycker, 2020, PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial, BMC Cancer, 20, 1, 10.1186/s12885-020-06911-4

Kwon, 2011, Solitary testicular metastasis of prostate cancer mimicking primary testicular cancer, Korean J Urol, 52, 718, 10.4111/kju.2011.52.10.718

Ochoa, 2017, Metastasectomy of abdominal wall lesions due to prostate cancer detected through PET/CT gallium 68-PMSA: first case report, Urol Case Reports, 12, 42, 10.1016/j.eucr.2017.01.008

Compérat, 2007, Late recurrence of a prostatic adenocarcinoma as a solitary splenic metastasis, Urol Int, 78, 86, 10.1159/000096942

Ost, 2020, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial, J Clin Oncol, 38, 10, 10.1200/JCO.2020.38.6_suppl.10

Battaglia, 2019, Metastasectomy for visceral and skeletal oligorecurrent prostate cancer, World J Urol, 37, 1543, 10.1007/s00345-019-02716-8

Devos, 2020, Oncological outcomes of metastasis-directed therapy in oligorecurrent prostate cancer patients following radical prostatectomy, Cancers (Basel), 12, 1, 10.3390/cancers12082271

Miura, 2020, Metastasis-directed therapy and prostate cancer : a systematic review, Minerva Urol Nefrol, 72, 531, 10.23736/S0393-2249.20.03779-0

Mazzone, 2019, The effect of lymph node dissection in metastatic prostate cancer patients treated with radical prostatectomy: a contemporary analysis of survival and early postoperative outcomes, Eur Urol Oncol, 2, 541, 10.1016/j.euo.2018.10.010

O’Shaughnessy, 2017, A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer, Urology, 102, 164, 10.1016/j.urology.2016.10.044

Thông tin
Thông tin xuất bản

ESMO Open

Tập 7

100597

Thông tin tác giả